Triamcinolone
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Triamcinolone: From Autoimmune and Inflammatory Disease to Alopecia Mucinosa
One-Sentence Summary
Triamcinolone is a potent corticosteroid, originally used for autoimmune and inflammatory conditions (such as Crohn disease, adrenocortical insufficiency and eosinophilic pneumonia) and for some haematological conditions (such as acute lymphoblastic leukaemia). The TxGNN model predicts it may be effective for alopecia mucinosa (follicular mucinosis), but there are currently 0 clinical trials and only 2 publications (both case-level, one of which concerns a different drug), so support for this direction is limited.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, Crohn disease, adrenocortical insufficiency and others (from the knowledge graph; the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 13 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, triamcinolone is a potent corticosteroid with anti-inflammatory and immunosuppressive effects. Its efficacy in inflammatory and autoimmune conditions is established, and mechanistically it may be applicable to alopecia mucinosa.
Intralesional or topical corticosteroids are commonly used in follicular mucinosis to reduce perifollicular lymphocytic inflammation, which gives the prediction some biological plausibility. However, the supporting literature is limited to case reports. The model score is high, but it is not backed by clinical trials.
Other predictions from the model (for context):
- Folliculitis decalvans (L3): a neutrophilic scarring alopecia in which intralesional triamcinolone is an established adjunct. A retrospective review of 23 patients supports corticosteroid use within multimodal regimens, but it does not evaluate triamcinolone directly. This is the best-supported of the predictions.
- Idiopathic steroid-sensitive nephrotic syndrome (L4): the support reflects the glucocorticoid class (prednisone/prednisolone are standard first-line), not triamcinolone specifically.
- Alopecia universalis with onychodystrophy and vitiligo (L5): the autoimmune features make corticosteroid use plausible, but there is no direct evidence, and alopecia universalis responds poorly to intralesional therapy.
- Telogen effluvium (L5): a typically non-inflammatory, self-limiting condition with no clear mechanistic rationale for a corticosteroid.
- Sporadic idiopathic steroid-resistant nephrotic syndrome (L5): by definition unresponsive to glucocorticoids, so the prediction is mechanistically counterintuitive.
- Alopecia antibody deficiency, hereditary hypotrichosis with recurrent skin vesicles, alopecia–intellectual disability–hypergonadotropic hypogonadism syndrome, and atrichia with papular lesions (all L5): prediction only, with no clinical evidence and no plausible mechanistic link.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14170262 | 1964 | Case report | Hifuka kiyo. Acta dermatologica | Case of alopecia mucinosa (Pinkus) / follicular mucinosis (Jablonska); no abstract available |
| 23968145 | 2014 | Case report | International journal of dermatology | Idiopathic follicular mucinosis successfully treated with topical bexarotene gel (not a corticosteroid); notes that no uniformly effective therapy exists |
Neither publication evaluates triamcinolone directly.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07820P | TRIAMNONE CREAM 0.1% w/w | Cream | Not stated in the available records |
| SIN11484P | ORREPASTE 0.1% w/w | Paste | Not stated in the available records |
| SIN17090P | ARCATUS® Triamcinolone acetonide suspension for injection 40 mg/mL | Injection, suspension | Not stated in the available records |
| SIN04004P | ORAMEDY PASTE 1 mg/g | Paste | Not stated in the available records |
| SIN05787P | SHINCORT I.M. INJECTION 40 mg/ml | Injection | Not stated in the available records |
There are 13 valid single-ingredient registrations in total, covering cream, paste, lotion and injectable forms.
Safety Considerations
- Disease-level cautions from the knowledge graph (not label text): the graph links triamcinolone to caution or contraindication in conditions including hypertension, congestive heart failure, epilepsy, liver disease, gallbladder disease, hyperglycaemia, measles, herpes simplex virus keratitis, and various pituitary hormone deficiency disorders (e.g. hypopituitarism, Sheehan syndrome, Kallmann syndrome). Also listed are urea cycle disorders (carbamoyl phosphate synthetase I deficiency, citrullinemia, hyperargininemia).
- Drug Interactions: 100 interactions were identified. Among those reviewed, the one rated Major is adalimumab. Moderate interactions include zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alefacept, alemtuzumab, aliskiren and tetanus toxoid vaccine. Minor interactions include formoterol and salbutamol.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there are no registered clinical trials, and the only two publications are old or indirect case reports (one concerns bexarotene, not a corticosteroid). Support currently rests on mechanistic plausibility and general clinical practice with corticosteroids, not on direct evidence for triamcinolone. Package insert safety data are also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (a blocking gap for safety screening)
- Mechanism of action data
- Triamcinolone-specific clinical evidence in follicular mucinosis (e.g. case series or controlled studies of intralesional/topical use)
- Approved indication text for the Singapore licences, and confirmation that an appropriate route/formulation is available (topical and injectable forms are registered)
- Consider prioritising folliculitis decalvans for further review, since it has the strongest evidence level (L3) among the model's predictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.